Evidence map›Paper›PMID 35441018›Full record

ArticleClinical case reports2022

Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease.

Hiroyuki Sugiura, Nobuo Sezaki, Tatsunori Ishikawa, Taiga Kuroi, Sachiyo Okamoto, Naho Nomura, Taro Masunari, Yukio Nakasako, Toru Kiguchi, Mitsune Tanimoto

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hiroyuki SugiuraDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.ORCID https://orcid.org/0000-0002-2400-0086
Nobuo SezakiDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Tatsunori IshikawaDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Taiga KuroiDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Sachiyo OkamotoDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Naho NomuraDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Taro MasunariDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Yukio NakasakoDepartment of Diabetology and Nephrology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Toru KiguchiDepartment of Diabetes Endocrinology and Hematology Dokkyo Medical University Saitama Medical Center Koshigaya Japan.
Mitsune TanimotoDepartment of Hematology Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers Fukuyama Japan.
Chugoku Central Hospital · JPDokkyo Medical University Saitama Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venetoclax is a promising new drug for relapsed or refractory chronic lymphocytic leukemia (CLL). However, venetoclax use had not been reported in severe chronic kidney disease (CKD) patients. We report the first case of relapsed CLL in a severe CKD patient that was successfully treated with venetoclax.

Indexed as

chronic lymphocytic leukemiasevere chronic kidney diseasetumor lysis syndromevenetoclax

Identifiers

PMID35441018
PMCPMC9010727
OpenAlexW4225966371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.